Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryDec032018	Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Humanized Antibody Fragments and Antigen-Binding Domains Targeting BCMA SAN DIEGO , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company Read All »	View HTML
Toggle SummaryDec082011	Fate Therapeutics Secures Foundational Patent for IPS Cell Programming U.S. Patent Covers Key Compositions Used in the Generation of Human Induced Pluripotent Stem Cells Read All »	View HTML Fate Therapeutics secures foundational patent for IPS cell programming 136.2 KB
Toggle SummaryApr102014	Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Patent and Trademark Office (PTO) has issued Patent No. Read All »	View HTML Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics 14.6 KB
Toggle SummaryJul312014	Fate Therapeutics Secures Up to $20 Million in Debt Financing Strengthened Cash Position Expected to Fund Company Through 2015 Read All »	View HTML Fate Therapeutics Secures Up to $20 Million in Debt Financing 15.3 KB
Toggle SummaryDec132021	Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting 5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab 13 of 19 Patients Achieve Objective Response with Single Dose of FT596 at 90 Million and 300 Million Cell Dose; 10 of 11 Patients Read All »	View HTML
Toggle SummaryOct282015	Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions Proprietary Pluripotent Cell Platform Has Broad Applicability for Development of Off-the-Shelf Cancer Immunotherapies Read All »	View HTML Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions 20.8 KB
Toggle SummaryNov162011	Fate Therapeutics Strengthens its iPSC Platform Secures U.S. Patent to Novel Small Molecule Modulator of Pluripotent Stem Cells Read All »	View HTML Fate Therapeutics strengthens its iPSC platform 10 KB
Toggle SummaryDec042012	Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-Based Protein Therapeutics Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-Based Protein Therapeutics San Diego, CA – Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today several advancements in its goal Read All »	View HTML Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-Based Protein Therapeutics 11.2 KB
Toggle SummaryJun302014	Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders SAN DIEGO , June 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has submitted an investigational new drug (IND) application to Read All »	View HTML Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders 21.5 KB
Toggle SummaryMar022017	Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting SAN DIEGO, March 02, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that three abstracts describing the Company's programs Read All »	View HTML Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting 19.4 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.